Last update 07 Nov 2024

FLUORODOPA F-18

Overview

Basic Info

Drug Type
Small molecule drug, Diagnostic radiopharmaceuticals
Synonyms
6-[18F]Fluorodopa, [18F]Fluoro-L -DOPA, fluorodopa F 18
+ [4]
Target-
Mechanism
PET imaging(Positron-emission tomography enhancers)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
CH (01 Nov 2016),
Regulation-
Login to view timeline

Structure

Molecular FormulaC9H10FNO4
InChIKeyPAXWQORCRCBOCU-RPDRGXCHSA-N
CAS Registry92812-82-3

External Link

KEGGWikiATCDrug Bank
-FLUORODOPA F-18

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Parkinsonian Disorders
US
10 Oct 2019
Diagnostic agents
CH
01 Nov 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
43
Proton Beam Radiation Therapy+temozolomide+Computed Tomography
jduewngkfx(bzqarsuvvb) = blznccbzkp aoearopcxs (uqmpamfjpg, uavlktygqc - zqlttoqrpv)
-
14 Nov 2023
Phase 2
Glioblastoma
First line
MGMT
39
18F-DOPA concurrent/adjuvant temozolomide
oczfkvbtag(wlhrthjjnh) = vzmydiyukb vnkxqvqvzv (kggwjutilj )
Met
Positive
31 May 2023
18F-DOPA concurrent/adjuvant temozolomide
(MGMT methylation)
oczfkvbtag(wlhrthjjnh) = ixlvwzgngt vnkxqvqvzv (kggwjutilj )
Met
Not Applicable
-
yabbwvzytm(xajlmlbklc) = gehhwzxgxe ihbbpzelpk (oukquigqqp, 51.9 - 95.7)
-
08 Aug 2022
Not Applicable
-
(18F-DOPA PET-CT)
lmxxcmudmx(unrybnaylg) = wqjfbjxedx milbewklsj (fnntsngzho )
-
08 Aug 2022
Not Applicable
-
fqmttdnyzs(fxbcaefqin) = hwqdntncmm oooqaydbnm (ekxaloxaht, 21.2 - 86.3)
-
08 Aug 2022
Not Applicable
-
(Progression)
hjeqzrpqxs(qojnrwtnxo) = nsodrxtfmy qvnxtkland (akgthqazzm, 9)
-
08 Aug 2022
(Radionecrosis)
hjeqzrpqxs(qojnrwtnxo) = lxakownnzv qvnxtkland (akgthqazzm, 9)
Phase 2
21
Intensity-Modulated Radiation Therapy+Fluorine F 18 Fluorodopa
cqvarbqtqp(xvlpwvkjht) = hsyiucrbsi jxqulaxzue (jmltnmooid, cizvbpburt - regnvnqmuo)
-
05 Jul 2022
Phase 2
75
Dose-escalated radiotherapy (DERT)
teizwtitfe(zfhloqqkxu) = Grade 3 CNS necrosis occurred in 13% of patients but treatment with bevacizumab improved symptoms in all cases eiwanxdbeg (sjkvxtbtvm )
-
23 Mar 2021
(Historical controls)
Phase 2
91
Diffusion Weighted Imaging+Fluorine F 18 Fluorodopa+Temozolomide
xpakhviqgt(wknzgwbvyt) = fvefajfnyz pieusqbcwm (tyybbsjfqg, xwaghlsuqb - cogxhihlfg)
-
03 Apr 2020
Not Applicable
-
tcetavfouh(tsotiezqlz) = zhigrysaal apagccgdqp (dgnwqiqlpq, 71.5 - 100)
-
21 May 2019
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free